Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers
- PMID: 17922561
- DOI: 10.2165/00003088-200746110-00004
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers
Abstract
Background and objective: Respiratory depression is a potentially life-threatening adverse effect of opioid therapy. It has been postulated that the difficulty of reversing buprenorphine-induced respiratory depression is caused by slow receptor association-dissociation kinetics at the opioid mu receptor. The aim of this study was to characterise the pharmacodynamic interaction between buprenorphine and naloxone in healthy volunteers.
Methods: A competitive pharmacodynamic interaction model was proposed to describe and predict the time course of naloxone-induced reversal of respiratory depression. The model was identified using data from an adaptive naloxone dose-selection trial following intravenous administration of buprenorphine 0.2mg/70kg or 0.4mg/70kg.
Results: The pharmacokinetics of naloxone and buprenorphine were best described by a two-compartment model and a three-compartment model, respectively. A combined biophase equilibration-receptor association-dissociation pharmacodynamic model described the competitive interaction between buprenorphine and naloxone at the opioid mu receptor. For buprenorphine, the values of the rate constants of receptor association (k(on)) and dissociation (k(off)) were 0.203 mL/ng/min and 0.0172 min(-)(1), respectively. The value of the equilibrium dissociation constant (K(D)) was 0.18 nmol/L. The half-life (t((1/2))) of biophase equilibration was 173 minutes. These estimates of the pharmacodynamic parameters are similar to values obtained in the absence of naloxone co-administration. For naloxone, the half-life of biophase distribution was 6.5 minutes.
Conclusions: Because of the slow receptor association-dissociation kinetics of buprenorphine in combination with the fast elimination kinetics of naloxone, naloxone is best administered as a continuous infusion for reversal of buprenorphine-induced respiratory depression.
Similar articles
-
Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.Clin Pharmacol Ther. 2007 Jan;81(1):50-8. doi: 10.1038/sj.clpt.6100025. Clin Pharmacol Ther. 2007. PMID: 17185999 Clinical Trial.
-
Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study.Anesthesiology. 2010 Jun;112(6):1417-27. doi: 10.1097/ALN.0b013e3181d5e29d. Anesthesiology. 2010. PMID: 20461002 Clinical Trial.
-
Opioid-induced respiratory effects: new data on buprenorphine.Palliat Med. 2006;20 Suppl 1:s3-8. Palliat Med. 2006. PMID: 16764215 Clinical Trial.
-
Non-analgesic effects of opioids: opioid-induced respiratory depression.Curr Pharm Des. 2012;18(37):5994-6004. doi: 10.2174/138161212803582469. Curr Pharm Des. 2012. PMID: 22747535 Review.
-
Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression.Anesthesiology. 2010 Jan;112(1):226-38. doi: 10.1097/ALN.0b013e3181c38c25. Anesthesiology. 2010. PMID: 20010421 Review.
Cited by
-
Translational PK-PD modeling in pain.J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):401-18. doi: 10.1007/s10928-012-9282-0. Epub 2012 Nov 30. J Pharmacokinet Pharmacodyn. 2013. PMID: 23197248 Review.
-
Transdermal buprenorphine patch in the management of post-operative pain in orthopaedic patients: a systematic review looking at efficacy, safety, adverse effects and cost-benefit analysis.Eur J Orthop Surg Traumatol. 2025 May 30;35(1):221. doi: 10.1007/s00590-025-04334-0. Eur J Orthop Surg Traumatol. 2025. PMID: 40447820
-
A Surface-Enhanced Raman Spectral Library of Important Drugs Associated With Point-of-Care and Field Applications.Front Chem. 2019 Oct 25;7:706. doi: 10.3389/fchem.2019.00706. eCollection 2019. Front Chem. 2019. PMID: 31709234 Free PMC article.
-
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.Pharm Res. 2011 Oct;28(10):2490-504. doi: 10.1007/s11095-011-0477-7. Epub 2011 Jun 7. Pharm Res. 2011. PMID: 21647790 Free PMC article.
-
Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization.Front Pharmacol. 2023 Jan 19;14:1089862. doi: 10.3389/fphar.2023.1089862. eCollection 2023. Front Pharmacol. 2023. PMID: 36744255 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous